Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TCRX
Upturn stock ratingUpturn stock rating

Tscan Therapeutics Inc (TCRX)

Upturn stock ratingUpturn stock rating
$1.81
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TCRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $8.57

1 Year Target Price $8.57

Analysts Price Target For last 52 week
$8.57 Target price
52w Low $1.02
Current$1.81
52w High $6.22

Analysis of Past Performance

Type Stock
Historic Profit -47.76%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 102.71M USD
Price to earnings Ratio -
1Y Target Price 8.57
Price to earnings Ratio -
1Y Target Price 8.57
Volume (30-day avg) 8
Beta 0.99
52 Weeks Range 1.02 - 6.22
Updated Date 08/15/2025
52 Weeks Range 1.02 - 6.22
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.1

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.33
Actual -0.28

Profitability

Profit Margin -
Operating Margin (TTM) -1256.6%

Management Effectiveness

Return on Assets (TTM) -26.77%
Return on Equity (TTM) -63.33%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -18631133
Price to Sales(TTM) 14.76
Enterprise Value -18631133
Price to Sales(TTM) 14.76
Enterprise Value to Revenue 7.64
Enterprise Value to EBITDA 0.39
Shares Outstanding 52471400
Shares Floating 40823939
Shares Outstanding 52471400
Shares Floating 40823939
Percent Insiders 0.23
Percent Institutions 81.84

ai summary icon Upturn AI SWOT

Tscan Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Tscan Therapeutics, Inc. is a biopharmaceutical company focused on developing T-cell receptor (TCR)-engineered T cell therapies for the treatment of cancer. Founded in 2018, it has advanced several TCR-T cell therapy candidates into clinical development.

business area logo Core Business Areas

  • Oncology: Developing and commercializing TCR-T cell therapies to treat various cancers.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the biopharmaceutical industry. The company has a traditional biotech organizational structure with departments focusing on research, development, clinical operations, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • TSC-100: A TCR-T cell therapy targeting minor histocompatibility antigens (miHAs) for the treatment of hematologic malignancies post allogeneic hematopoietic cell transplantation (allo-HCT). Competitors include companies developing cell therapies for similar indications, such as bone marrow transplant complications.
  • TSC-101: A TCR-T cell therapy for solid tumors. Competitors include companies developing cell therapies or other immune-oncology therapies for solid tumors.

Market Dynamics

industry overview logo Industry Overview

The cell therapy market is rapidly growing, driven by advancements in immuno-oncology and gene editing technologies. It is a highly competitive and innovative field.

Positioning

Tscan Therapeutics focuses on TCR-T cell therapies, which allows them to target both hematologic malignancies and solid tumors. Their competitive advantage lies in their TCR discovery platform and miHA target selection.

Total Addressable Market (TAM)

The TAM for cell therapies is projected to reach tens of billions of dollars. Tscan Therapeutics is positioned to capture a share of this market by developing TCR-T cell therapies for specific cancer subtypes.

Upturn SWOT Analysis

Strengths

  • Proprietary TCR discovery platform
  • Experienced management team
  • Clinical-stage pipeline
  • Focus on validated targets

Weaknesses

  • High cash burn rate
  • Dependence on clinical trial success
  • Manufacturing complexities of cell therapies
  • Limited commercial infrastructure

Opportunities

  • Expanding pipeline with additional TCR-T cell therapies
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Regulatory approvals

Threats

  • Competition from other cell therapy companies
  • Clinical trial failures
  • Regulatory hurdles
  • Manufacturing challenges

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • GILD
  • NVS

Competitive Landscape

Tscan Therapeutics competes with other cell therapy companies. Its advantage lies in its TCR discovery platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data will be added when available.

Future Projections: Future projection data will be added when available.

Recent Initiatives: Recent initiatives include advancing clinical trials for TSC-100 and TSC-101, expanding TCR discovery efforts, and securing partnerships.

Summary

Tscan Therapeutics is a clinical-stage biopharmaceutical company focused on TCR-T cell therapies. Its strengths include its proprietary technology, but it faces risks associated with clinical development and competition. The company needs to successfully navigate the regulatory landscape and demonstrate clinical efficacy to achieve long-term success. They need to watch out for cash burn as they need funding until they are making substantial revenues.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tscan Therapeutics Inc

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2021-07-16
CEO & Director Dr. Gavin MacBeath Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 194
Full time employees 194

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.